Last reviewed · How we verify

ODM-108 Part I — Competitive Intelligence Brief

ODM-108 Part I (ODM-108 Part I) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Small molecule (investigational). Area: Other.

discontinued Small molecule (investigational) Not disclosed Other Small molecule Live · refreshed every 30 min

Target snapshot

ODM-108 Part I (ODM-108 Part I) — Orion Corporation, Orion Pharma. ODM-108 Part I mechanism of action is not publicly disclosed; Phase 1 development was terminated.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ODM-108 Part I TARGET ODM-108 Part I Orion Corporation, Orion Pharma discontinued Small molecule (investigational) Not disclosed

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Small molecule (investigational) class)

  1. Orion Corporation, Orion Pharma · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ODM-108 Part I — Competitive Intelligence Brief. https://druglandscape.com/ci/odm-108-part-i. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: